Company intelligence / Profile preview

Actinium Pharmaceuticals, Inc.

New York, New York, United States of Americaactiniumpharma.com ↗

Ownership: Public · ATNM
Employees: ~37
Development stage: Other

Overview

Actinium has positive Phase 3 SIERRA trial results for Iomab-B. The company is advancing multiple clinical programs including Actimab-A in various combinations for AML and solid tumors, and Iomab-ACT for cell and gene therapy conditioning. Clinical data for multiple programs is expected throughout 2025.

Therapeutic areas: OncologyHematology
Modalities: Antibody Radiation Conjugates (ARCs)Targeted radiotherapies
Industry: Biotech

Drug pipeline

16 assets

lintuzumab

15 more assets in the full pipeline.

Partnerships

National Cancer Institute (NCI)Fred Hutchinson Cancer Research CenterUniversity of Texas SouthwesternColumbia UniversityTaiho Oncology

Financials

Market cap: $40.9M
Total revenue: $90K
Enterprise value: $5.7M

Beyond the preview

Go deeper on Actinium Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actinium Pharmaceuticals, Inc..